Abstract
A new series of hybrid 2-quinolinone derivatives were synthesized and confirmed using IR, H-1 NMR, C-13 NMR, and elemental analyses. The cytotoxic activities of some synthesized hybrid 2-quinolinone derivatives were evaluated on human breast carcinoma cells (MCF-7) using the MTT assay. Cell cycle specificity analysis of the 7-hydroxy-4-methyl-3-bromo-2-oxo-1-(p-chlorobenzoyl) methylquinoline compound revealed cell cycle arrest at the S phase. In addition, this compound showed potent topoisomerase (topo) II inhibitory activity in nano-molar concentration compared to doxorubicin as a reference compound. Also, this compound showed moderate beta-tubulin polymerization inhibition activity compared to known tubulin polymerization inhibitor combretastatin A-4.